CVI Holdings LLC Invests $1.15 Million in CARGO Therapeutics, Inc. (NASDAQ:CRGX)

CVI Holdings LLC purchased a new position in CARGO Therapeutics, Inc. (NASDAQ:CRGX) during the 2nd quarter, HoldingsChannel.com reports. The fund purchased 70,000 shares of the company’s stock, valued at approximately $1,149,000. CARGO Therapeutics comprises approximately 1.0% of CVI Holdings LLC’s portfolio, making the stock its 15th biggest position.

Other institutional investors have also modified their holdings of the company. Ameritas Investment Partners Inc. acquired a new position in shares of CARGO Therapeutics in the first quarter worth about $48,000. American International Group Inc. acquired a new position in shares of CARGO Therapeutics in the first quarter worth about $237,000. BNP Paribas Financial Markets acquired a new position in shares of CARGO Therapeutics in the first quarter worth about $238,000. California State Teachers Retirement System acquired a new position in shares of CARGO Therapeutics in the first quarter worth about $337,000. Finally, Swiss National Bank acquired a new position in shares of CARGO Therapeutics in the first quarter worth about $636,000. Institutional investors and hedge funds own 93.16% of the company’s stock.

Insider Transactions at CARGO Therapeutics

In other news, CFO Anup Radhakrishnan sold 1,600 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $25.28, for a total transaction of $40,448.00. Following the sale, the chief financial officer now directly owns 6,446 shares in the company, valued at approximately $162,954.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Anup Radhakrishnan sold 1,600 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $25.28, for a total value of $40,448.00. Following the completion of the transaction, the chief financial officer now directly owns 6,446 shares of the company’s stock, valued at approximately $162,954.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Gina Chapman sold 2,975 shares of the stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $25.03, for a total value of $74,464.25. Following the completion of the transaction, the chief executive officer now directly owns 103,905 shares of the company’s stock, valued at $2,600,742.15. The disclosure for this sale can be found here. Insiders own 1.38% of the company’s stock.

Analyst Ratings Changes

CRGX has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $33.00 price target on shares of CARGO Therapeutics in a research note on Tuesday, August 13th. Chardan Capital initiated coverage on CARGO Therapeutics in a research note on Monday, July 8th. They set a “buy” rating and a $28.00 price objective on the stock. Finally, Piper Sandler cut their price objective on CARGO Therapeutics from $37.00 to $34.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, CARGO Therapeutics currently has an average rating of “Buy” and a consensus target price of $30.33.

CARGO Therapeutics Stock Performance

Shares of NASDAQ CRGX opened at $17.42 on Friday. The stock’s 50 day moving average price is $18.21 and its two-hundred day moving average price is $19.26. CARGO Therapeutics, Inc. has a 52-week low of $13.14 and a 52-week high of $33.92.

CARGO Therapeutics (NASDAQ:CRGX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($1.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.04. On average, analysts anticipate that CARGO Therapeutics, Inc. will post -4.37 EPS for the current year.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.